Pricing Log in Create free account
Saturday 17 October 2026 Export YI’s income statement to Excel — free account

111, Inc. Sponsored ADR

YI Healthcare Medical Distribution

111, Inc. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.8 billion, down 9.00% from fiscal 2024. In the quarter to March 2026, revenue fell 29.6%, EPS fell 200.0%, free cash flow fell 185.7% and total debt rose 82.5%, each against the same quarter a year earlier.

3.09 0.00 0.00%
Market cap
$16.0M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
5/9
Altman Z
3.31
Beneish M
−3.28
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.37
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — 9 — — — — —
Insider Ownership 42.13%

Capital & Financial Ratios $m

Market Cap 16.04
Revenue 1,651.50
Net Income (3.22)
Free Cash Flow (11.78)
Net Debt (20.15)
Current Ratio 1.08
Debt/Equity (0.34) (negative: negative equity)
P/E ratio 0.00
Fwd P/E 0.00
P/S ratio 0.02
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 9.40%
Next Y EPS Growth —
Next Y revenue growth 33.58% (at or above 10%: strong)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.0×, against a ten-year median of 0.0×; over the ten years it ranged from −0.1× in 2019 to 0.0× in 2026.
P/S against its own 10 years 45.65%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 95 71 87 57
Receivables 76 57 37 27
Inventory 200 190 143 147
Other — — — —
413 363 304 270
2023 2024 2025 Q'26
Payables 224 236 183 176
ST’ Debt 48 22 27 37
Other — — — —
387 321 279 249

Compound Annual Growth %

10y 5y 3y
Sales — 7.39% (2.88%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 342 — — — —
’25 486 448 422 440 1,795
’24 489 471 513 500 1,973
’23 538 480 502 585 2,105
’22 470 453 471 565 1,960
’21 396 468 519 566 1,950
’20 223 230 348 457 1,257
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (13) — — — —
’25 16 (8) 5 4 17
’24 15 13 17 (8) 36
’23 (18) (22) 5 (29) (63)
’22 (11) (4) 3 9 (3)
’21 (40) (2) (17) (50) (108)
’20 (16) 18 4 (24) (18)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (13) — — — —
’25 16 (8) 5 4 16
’24 15 13 17 (8) 34
’23 (18) (22) 5 (29) (64)
’22 (11) (4) 3 9 (8)
’21 (40) (2) (17) (50) (118)
’20 (16) 18 4 (24) (22)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.60) — — — —
’25 (0.20) (0.40) (0.20) (0.20) (1.00)
’24 (0.20) (0.20) (0.20) (0.04) (0.10)
’23 (0.60) (1.00) (1.60) (3.40) (6.60)
’22 (2.00) (1.80) (1.60) (2.00) (7.20)
’21 (2.80) (3.00) (4.80) (2.20) (12.60)
’20 (2.20) (1.60) (2.00) (2.40) (8.40)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — 6.00 2.29 5.20 3.01 1.37 1.19 0.50 0.41

Analyst estimates 2026–2028

Powerpack
High — — 16.83 10.80 8.70 45.88 4.00 3.48 1.85 11.35
People
People Employees — 1,117 1,350 1,932 2,189 2,114 1,657 1,520 1,238 1,063
Revenue/emp, $m 0.00 0.13 0.19 0.29 0.57 0.92 1.18 1.39 1.59 1.69
Income, $m
Income, $m Revenue 132 145 260 568 1,257 1,950 1,960 2,105 1,973 1,795
Gross margin, % 9.09 9.46 5.84 4.18 4.46 5.00 6.21 5.68 5.76 5.76
EBT (55) (38) (56) (72) (72) (97) (55) (50) (3) (3)
EBT margin, % (41.67) (25.99) (21.39) (12.70) (5.69) (5.00) (2.78) (2.36) (0.14) (0.18)
Net income (55) (38) (56) (72) (72) (97) (55) (50) (3) (3)
Depreciation 2 2 2 2 2 4 6 3 2 2
Per share, $
Per share, $ Revenue 1.61 40.28 52.24 69.37 152.58 235.11 235.21 249.74 229.63 206.35
Earnings (0.38) (10.47) (11.10) (8.80) (8.40) (12.60) (7.20) (6.60) (0.10) (1.00)
Cash flow (0.71) (8.58) (10.03) (8.99) (2.17) (13.03) (0.40) (7.47) 4.19 1.96
Capex 0.00 (0.29) (0.43) (0.43) (0.48) (1.18) (0.53) (0.14) (0.23) (0.07)
Free cash flow (0.71) (8.86) (10.46) (9.42) (2.65) (14.21) (0.93) (7.61) 3.96 1.89
Book value 1.92 (39.66) 35.79 13.58 7.56 (2.88) (7.11) (9.94) (10.49) (11.86)
Shares, m 82 4 5 8 8 8 8 8 9 9
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 0.00 0.00 0.00 0.10 0.05 0.01 0.01 0.01 0.00 0.01
P/B 0.00 0.00 0.14 0.50 0.92 0.00 0.00 0.00 0.00 0.00
EV/Sales 0.00 0.00 0.00 (0.06) (0.12) (0.04) (0.04) (0.02) (0.02) (0.02)
EV/FCF 0.00 0.00 0.00 0.43 5.86 0.62 3.30 0.40 (2.43) (4.73)
Cash, $m
Cash, $m Operating cash flow (58) (31) (50) (74) (18) (108) (3) (63) 36 17
Capex (1) (1) (2) (4) (4) (10) (4) (1) (2) (1)
Free cash flow (58) (32) (52) (77) (22) (118) (8) (64) 34 16
Balance, $m
Balance, $m Working capital 105 80 173 102 190 105 74 27 42 24
Total debt — — — 14 35 41 26 48 22 27
Net debt (92) (70) (161) (87) (213) (107) (108) (47) (49) (61)
Shareholders’ equity 158 (143) 178 111 62 (24) (59) (84) (90) (103)
Returns, %
Returns, % ROA (36.72) (25.19) (32.49) (31.46) (20.13) (21.96) (12.12) (11.78) (2.17) (2.73)
ROIC 0.00 0.00 (213.47) (180.08) 0.00 0.00 0.00 0.00 0.00 0.00
ROE 51.65 31.08 (313.93) (49.64) (80.68) (547.31) 145.42 77.35 10.20 9.82
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

111, Inc. Sponsored ADR vs peers in Medical Distribution (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CAH Cardinal Health, Inc. $58.8B 35.0× 23.3× +5.84% (above 0%: growing) +68.32% (above 0%: growing) +10.87% (above 0%: growing) 4.02% 1.14% Compare
HSIC Henry Schein, Inc. $9.7B 25.0× 18.5× +6.73% (above 0%: growing) +16.90% (above 0%: growing) +140.91% (above 0%: growing) 31.84% 4.95% Compare
AHG Akso Health Group Sponsored ADR $1.2B — (loss-making) — (loss-making) +263.89% (above 0%: growing) n/m −12,975.04% (below 0%: shrinking) 0.00% 0.00% Compare
FOCL FocalTherics $154.8M — (loss-making) — (loss-making) +38.85% (above 0%: growing) n/m +21.49% (above 0%: growing) 55.59% (60.83%) Compare
COSM Cosmos Health Inc. $33.9M — (loss-making) 25.1× +28.76% (above 0%: growing) n/m +9.39% (above 0%: growing) 7.96% (15.41%) Compare
ACH Accendra Health, Inc. $20.1M — (loss-making) — (loss-making) −10.07% (below 0%: shrinking) n/m −1,624.82% (below 0%: shrinking) 42.95% (5.73%) Compare
HKPD Cellyan Biotechnology Co., Ltd $17.1M — — — — −90.45% (below 0%: shrinking) — — Compare
YI 111, Inc. Sponsored ADR $16.0M — (loss-making) — (loss-making) −29.61% (below 0%: shrinking) n/m −185.70% (below 0%: shrinking) 5.33% (0.85%)
SNYRQ Synergy CHC Corp. $1.3M — (loss-making) 1.6× −32.77% (below 0%: shrinking) n/m −148.51% (below 0%: shrinking) 72.29% (10.32%) Compare
Median of peers $94.3M — 20.9× +6.73% — −40.53% 31.84% (5.73%)

All 11 Medical Distribution stocks →

111, Inc. Sponsored ADR (YI) key facts

  • Concern: 111, Inc. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.8 billion, down 9.00% from fiscal 2024.
  • 111, Inc. Sponsored ADR (YI) is a Medical Distribution company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, YI traded at $3.09, a market capitalization of $16.0 million.
  • Return on equity was 9.82% and debt-to-equity -0.34.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 3.31 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

111, Inc. Sponsored ADR (YI) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/YI · Data as of Mar 31, 2026 · For information only; not investment advice. · © 2026 stockrow.com